SOAT1 and rheumatoid arthritis: Although the average and maximal inhibition percentages are not directly comparable, the current data nevertheless suggest that the in vitro studies may overestimate the inhibitory potential of tofacitinib on JAK-STAT pathway activation in RA patients in vivo.